PALISADE BIO, INC. (PALI) SEC Filings & Earnings Calls

Clinical-stage biotech with no approved products; history of net losses

“The Company has experienced net operating losses and negative cash flows from operations since its inception.” · word for word

Dependence on PALI-2108 clinical success

“The Company's lead clinical product candidate, PALI-2108, is being advanced into Phase 2 clinical trials” · word for word

Net loss increased significantly to $10.6M from $2.8M due to higher R&D and G&A expenses as the company advances PALI-2108 into Phase 2.

“Net loss was $10.6 million... compared to a net loss of $2.8 million for the three months ended June 30, 2025.”

Phase 2 trials still in early stages; primary efficacy readouts not expected until H2 2027 or later.

“Primary efficacy readout expected 2H 2027 for ASCENTRA-UC; early 2028 for ASCENTRA-CD.”

Clinical trial failure risk

“The Company has a limited operating history, and the sales and income potential of the Company’s business and market are unproven.” · word for word

Dependence on single product candidate

“Our lead clinical product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.” · word for word

Clinical development risk; Phase 2 trials not yet initiated; prior results may not replicate.

“the risk that prior results, such as signals of safety, clinical response and efficacy, dosing or durability of effect, observed from preclinical or clinical trials with a limited number of patients, will not be replicated.” · word for word

Massive shareholder dilution

“Assuming full exercise of the pre-funded warrants issued in the Financing, we issued approximately 1,854.5% of the number of shares of our common stock that were outstanding prior to the Financing.” · word for word

Sustained losses and negative shareholder return

“Net Income or Loss: 2025: $16,781,000; 2024: $14,438,000; 2023: $12,300,000. Value of Initial Fixed $100 Investment Total Shareholder Return: 2025: $3.”

Pay-for-performance misalignment

“CEO compensation actually paid increased from $691,605 in 2024 to $22,746,084 in 2025 despite net loss widening and TSR collapsing to $3.”

Single asset dependency

“Our business depends on the successful clinical development, regulatory approval, and commercialization of our lead asset PALI-2108.” · word for word

Capital need / going concern risk

“We expect that our operations and development of PALI-2108 will require more capital than we currently have, and we cannot guarantee when or if we will be able to secure such additional funding.” · word for word

Material weakness in internal controls

“Our management has identified a material weakness in our internal control over financial reporting.” · word for word

License dependency (Giiant)

“We depend on our license agreement with Giiant to permit us to use patents and patent applications relating to PALI-2108. Termination of these rights ... could materially harm our business and prevent us from developing or commercializing PALI-2108.” · word for word

Supply chain concentration (China)

“We currently have agreements in place with foreign third parties in China and other countries to provide the necessary clinical supply of our API.” · word for word

Dependence on single product candidate PALI-2108

“Our business depends on the successful clinical development, regulatory approval, and commercialization of our therapeutic compounds, including our lead asset PALI-2108.” · word for word

Reliance on Giiant license agreement

“We depend on our license agreement with Giiant to permit us to use patents and patent applications relating to PALI-2108. Termination of these rights or the failure to comply with our obligations under the license agreement could materially harm our business and prevent us from developing or commercializing PALI-2108, our lead product candidate.” · word for word

No revenue from product sales

“We have a limited operating history and have never generated any revenues from product sales.” · word for word

Potential Nasdaq delisting

“Our common stock could be delisted from the Nasdaq Stock Market if we are unable to maintain compliance with the Nasdaq Stock Market’s continued listing standards.” · word for word

Significant dilution risk from warrant exercise and authorized share increase

“Potential issuance of up to 8,637,810 shares upon exercise of New Warrants and increase in authorized shares from 280M to 300M.”

Cash runway risk if warrants not exercised

“If the New Warrant cannot be exercised, we will not receive any such proceeds, which could adversely impact our ability to fund our operations.” · word for word